Evidence map›Paper›PMID 34611582›Full record

ArticleJNCI cancer spectrum2021

Smoking Cessation After Lung Cancer Diagnosis and the Risk of Second Primary Lung Cancer: The Multiethnic Cohort Study.

Sophia J Luo, Eunji Choi, Jacqueline V Aredo, Lynne R Wilkens, Martin C Tammemägi, Loïc Le Marchand, Iona Cheng, Heather A Wakelee, Summer S Han

Open access · goldAbstract read
In one paragraph

Article in JNCI cancer spectrum, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Sophia J LuoQuantitative Sciences Unit, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.ORCID 0000-0002-2040-9773
Eunji ChoiQuantitative Sciences Unit, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.ORCID 0000-0003-1315-1433
Jacqueline V AredoStanford University School of Medicine, Stanford, CA, USA.ORCID 0000-0003-0559-3565
Lynne R WilkensCancer Epidemiology Program, University of Hawaii Cancer Center, Honolulu, HI, USA.
Martin C TammemägiDepartment of Health Sciences, Brock University, St. Catharines, Ontario, Canada.
Loïc Le MarchandCancer Epidemiology Program, University of Hawaii Cancer Center, Honolulu, HI, USA.ORCID 0000-0001-5013-980X
Iona ChengDepartment of Epidemiology and Biostatistics, University of California, San Francisco, CA, USA.ORCID 0000-0003-4132-2893
Heather A WakeleeStanford University School of Medicine, Stanford, CA, USA.ORCID 0000-0003-1136-980X
Summer S HanQuantitative Sciences Unit, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.ORCID 0000-0002-2013-6883
Stanford University · USUniversity of Hawaiʻi at Mānoa · USBrock University · CAUniversity of California, San Francisco · US

Funding

Understanding Population Differences in Cancer: The MEC StudyU01CA164973 · NCI · UNIVERSITY OF HAWAII AT MANOA · PI HAIMAN, CHRISTOPHER ALAN, LE MARCHAND, LOIC · 2015 to 2025
$37.4M
Evaluation of genetic, clinical, and environmental risk factors to establish effective screening strategies for second primary lung cancerR37CA226081 · NCI · STANFORD UNIVERSITY · PI HAN, SUMMER S · 2018 to 2024
$4.3M
NCI NIH HHS R37 CA226081NCI NIH HHS U01 CA164973
6 · The paper itself

Abstract

Background: Smoking cessation reduces lung cancer mortality. However, little is known about whether diagnosis of lung cancer impacts changes in smoking behaviors. Furthermore, the effects of smoking cessation on the risk of second primary lung cancer (SPLC) have not been established yet. This study aims to examine smoking behavior changes after initial primary lung cancer (IPLC) diagnosis and estimate the effect of smoking cessation on SPLC risk following IPLC diagnosis. Methods: The study cohort consisted of 986 participants in the Multiethnic Cohort Study who were free of lung cancer and active smokers at baseline (1993-1996), provided 10-year follow-up smoking data (2003-2008), and were diagnosed with IPLC in 1993-2017. The primary outcome was a change in smoking status from "current" at baseline to "former" at 10-year follow-up (ie, smoking cessation), analyzed using logistic regression. The second outcome was SPLC incidence after smoking cessation, estimated using cause-specific Cox regression. All statistical tests were 2-sided. Results: Among 986 current smokers at baseline, 51.1% reported smoking cessation at 10-year follow-up. The smoking cessation rate was statistically significantly higher (80.6%) for those diagnosed with IPLC between baseline and 10-year follow-up vs those without IPLC diagnosis (45.4%) during the 10-year period (adjusted odds ratio = 5.12, 95% confidence interval [CI] = 3.38 to 7.98; Conclusion: Lung cancer diagnosis has a statistically significant impact on smoking cessation. Quitting smoking after IPLC diagnosis may reduce the risk of developing a subsequent malignancy in the lungs.

Indexed as

AgedCohort StudiesEx-SmokersHumansIncidenceLogistic ModelsLung NeoplasmsMiddle AgedNeoplasms, Second PrimaryOdds RatioRacial GroupsRiskSmokersSmokingSmoking CessationTime Factors

Identifiers

PMID34611582
PMCPMC8487318
OpenAlexW3195670183

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.